Phase II Study of the PD1-inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma

Phase II Study of the PD1-inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma

The PD1/PD-L1 pathway may be a target for the treatment of T-cell lymphomas. Here, we treated 18 patients with relapsed or refractory T-cell lymphoma with the PD1-inhibitor pembrolizumab. Although we did not meet our primary objective of improving progression-free survival from 3 to 6 months, 5 of 1...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2019-04, Vol.19 (6), p.356-364.e3
Hauptverfasser: Barta, Stefan K., Zain, Jasmine, MacFarlane, Alexander W., Smith, Sonali M., Ruan, Jia, Fung, Henry C., Tan, Carlyn R., Yang, Yibin, Alpaugh, R. Katherine, Dulaimi, Essel, Ross, Eric A., Campbell, Kerry S., Khan, Nadia, Siddharta, Rawat, Fowler, Nathan H., Fisher, Richard I., Oki, Yasuhiro
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The PD1/PD-L1 pathway may be a target for the treatment of T-cell lymphomas. Here, we treated 18 patients with relapsed or refractory T-cell lymphoma with the PD1-inhibitor pembrolizumab. Although we did not meet our primary objective of improving progression-free survival from 3 to 6 months, 5 of 13 evaluable patients showed a response providing a benchmark for future studies.
ISSN:2152-2650
2152-2669
DOI:10.1016/j.clml.2019.03.022